Offline Calibration Procedure of the Drift Tube Detectors

A detailed description of the calibration of the DT local reconstruction algorithm is reported. After inter-channel synchronization has been verified through the appropriate hardware procedure, the time pedestal can be extracted directly from the distribution of the digi-times. Further corrections for time-of-flight and time of signal propagation are applied as soon as the three-dimensional hit position within the chamber is known. The different effects of the time pedestal miscalibration on the two main hit reconstruction algorithms are shown. The drift velocity calibration algorithm is based on the meantimer technique and different meantimer relations for different track angles and patterns of hit cells are used. This algorithm can also be used to determine the uncertainty of the reconstructed hit position

Local Muon Reconstruction in the Drift Tube Detectors

This note describes the local reconstruction in the Drift Tube subdetector of the CMS muon subsystem. The local reconstruction is the sequence of steps leading from the TDC measurements to reconstructed three-dimensional segments inside each DT chamber. These segments are the input to the muon track reconstruction. This note updates and supersedes CMS NOTE 2002/04

A sensitivity study of triboson production processes to dimension-6 EFT operators at the LHC

We present the first parton-level study of anomalous effects in triboson production in both fully and semi-leptonic channels in proton-proton collisions at 13 TeV at the Large Hadron Collider (LHC). The sensitivity to anomalies induced by a minimal set of bosonic dimension-6 operators from the Warsaw basis is evaluated with specific analyses for each final state. A likelihood-based strategy is employed to assess the most sensitive kinematic observables per channel, where the contribution of Effective Field Theory operators is parameterized at either the linear or quadratic level. The impact of the mutual interference terms of pairs of operators on the sensitivity is also examined. This benchmark study explores the complementarity and overlap in sensitivity between different triboson measurements and paves the way for future analyses at the LHC experiments. The statistical combination of the considered final states allows setting stringent bounds on five bosonic Wilson coefficients

Bisurea-Based Supramolecular Polymers for Tunable Biomaterials

Water-soluble supramolecular polymers show great potential to develop dynamic biomaterials with tailored properties. Here, we elucidate the morphology, stability and dynamicity of supramolecular polymers derived from bisurea-based monomers. An accessible synthetic approach from 2,4-toluene diisocyanate (TDI) as the starting material is developed. TDI has two isocyanates that differ in intrinsic reactivity, which allows to obtain functional, desymmetrized monomers in a one-step procedure. We explore how the hydrophobic/hydrophilic ratio affects the properties of the formed supramolecular polymers by increasing the number of methylene units from 10 to 12 keeping the hydrophilic hexa(ethylene glycol) constant. All bisurea-based monomers form long, fibrous structures with 3-5 monomers in the cross-section in water, indicating a proper hydrophobic\hydrophilic balance. The stability of the supramolecular polymers increases with an increasing amount of methylene units, whereas the dynamic nature of the monomers decreases. The introduction of one Cy3 dye affords modified supramolecular monomers, which co-assemble with the unmodified monomers into fibrous structures. All systems show excellent water-compatibility and no toxicity for different cell-lines. Importantly, in cell culture media, the fibrous structures remain present, highlighting the stability of these supramolecular polymers in physiological conditions. The results obtained here motivate further investigation of these bisurea-based building blocks as dynamic biomaterial.</p

Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms

A total of 63 myeloproliferative neoplasms [MPN; 9 polycythemia vera (PV), 32 essential thrombocythemia (ET), and 22 myelofibrosis (MF)] underwent spleen stiffness (SS) measurement by vibration-controlled transient elastography equipped with a novel spleen-dedicated module. Higher SS values significantly correlated with grade 2-3 bone marrow (BM) fibrosis (p=0.035), with hemoglobin level <10 g/dl (p=0.014) and with white blood cells 6510,000/ml (p=0.008). Median SS was significantly higher in MF patients compared to ET and PV (p=0.015). SS also correlated with higher JAK2 variant allele frequency (p=0.02). This study identifies SS as a potential noninvasive tool that reflects BM fibrosis and the mutational burden in MPN

Systemic amyloidosis and pneumatosis of bladder wall

A 72-year-old woman was admitted to our Department for syncopes, diarrhoea, and weight loss. We suspected the diagnosis of systemic amyloidosis after the detection of macroglossia and periorbital purpura, despite the biopsy of the previous year, that resulted negative for amyloid substance. We confirmed the diagnosis after the histological evidence of deposits of amyloid in bone marrow and the clinical evidence of pneumatosis of bladder wall. Chemotherapy improved only temporarily clinical condition

Beta-Blocker Use in Older Hospitalized Patients Affected by Heart Failure and Chronic Obstructive Pulmonary Disease: An Italian Survey From the REPOSI Register

Beta (β)-blockers (BB) are useful in reducing morbidity and mortality in patients with heart failure (HF) and concomitant chronic obstructive pulmonary disease (COPD). Nevertheless, the use of BBs could induce bronchoconstriction due to β2-blockade. For this reason, both the ESC and GOLD guidelines strongly suggest the use of selective β1-BB in patients with HF and COPD. However, low adherence to guidelines was observed in multiple clinical settings. The aim of the study was to investigate the BBs use in older patients affected by HF and COPD, recorded in the REPOSI register. Of 942 patients affected by HF, 47.1% were treated with BBs. The use of BBs was significantly lower in patients with HF and COPD than in patients affected by HF alone, both at admission and at discharge (admission, 36.9% vs. 51.3%; discharge, 38.0% vs. 51.7%). In addition, no further BB users were found at discharge. The probability to being treated with a BB was significantly lower in patients with HF also affected by COPD (adj. OR, 95% CI: 0.50, 0.37-0.67), while the diagnosis of COPD was not associated with the choice of selective β1-BB (adj. OR, 95% CI: 1.33, 0.76-2.34). Despite clear recommendations by clinical guidelines, a significant underuse of BBs was also observed after hospital discharge. In COPD affected patients, physicians unreasonably reject BBs use, rather than choosing a β1-BB. The expected improvement of the BB prescriptions after hospitalization was not observed. A multidisciplinary approach among hospital physicians, general practitioners, and pharmacologists should be carried out for better drug management and adherence to guideline recommendations